C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q2 2022
Institutional positions in C4 Therapeutics, Inc. as of Jun 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 113
- −10 vs. Q1 2022
- Shares held
- 39.4M
- +2.15M (+5.8%) vs. Q1 2022
- Total value
- $297.2M
- −$606.8M (−67.1%) vs. Q1 2022
- New holders
- 26
- 39 more added
- Sold out
- 36
- 34 more reduced
2 institutions that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q2 2022
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q1 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| State Street Corp | 716,443 | $5.40M | 0.00% | −1,511,316−67.8% | Reduced |
| Geode Capital Management, LLC | 721,425 | $5.44M | 0.00% | +53,606+8.0% | Added |
| Perceptive Advisors LLC | 766,231 | $5.78M | 0.18% | −1,316,492−63.2% | Reduced |
| Janus Henderson Group PLC | 849,600 | $6.41M | 0.00% | −237,182−21.8% | Reduced |
| Pictet Asset Management SA | 1,136,854 | $8.57M | 0.01% | +5,413+0.5% | Added |
| Bain Capital Life Sciences Investors, LLC | 1,642,210 | $12.4M | 1.45% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,960,713 | $14.8M | 0.00% | −61,429−3.0% | Reduced |
| RTW Investments, LP | 3,094,825 | $23.3M | 0.60% | −1,437,157−31.7% | Reduced |
| BlackRock Inc. | 3,397,598 | $25.6M | 0.00% | +257,608+8.2% | Added |
| Price T Rowe Associates Inc | 4,383,163 | $33.0M | 0.00% | +5,791+0.1% | Added |
| Wasatch Advisors Inc | 5,666,658 | $42.7M | 0.27% | +4,128,133+268.3% | Added |
| ArrowMark Colorado Holdings LLC | 5,842,407 | $44.1M | 0.50% | +3,933,384+206.0% | Added |
| Mirae Asset Global Investments Co., Ltd. | 22,119 | – | – | +22,119 | New |
| Pura Vida Investments, LLC | 0 | $0 | 0.00% | −624,860−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −503,888−100.0% | Sold out |
| Commodore Capital LP | 0 | $0 | 0.00% | −481,094−100.0% | Sold out |
| Clough Capital Partners L P | 0 | $0 | 0.00% | −356,181−100.0% | Sold out |
| PFM Health Sciences, LP | 0 | $0 | 0.00% | −284,772−100.0% | Sold out |
| EcoR1 Capital, LLC | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |
| Rafferty Asset Management, LLC | 0 | $0 | 0.00% | −135,392−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −131,250−100.0% | Sold out |
| Cypress Point Wealth Management, LLC | 0 | $0 | 0.00% | −118,573−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −89,662−100.0% | Sold out |
| Bellevue Group AG | 0 | $0 | 0.00% | −54,500−100.0% | Sold out |
| Eagle Health Investments LP | 0 | $0 | 0.00% | −47,200−100.0% | Sold out |
| AlphaCrest Capital Management LLC | 0 | $0 | 0.00% | −42,027−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −37,520−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −34,760−100.0% | Sold out |
| Gilder Gagnon Howe & Co LLC | 0 | $0 | 0.00% | −26,628−100.0% | Sold out |
| J. Goldman & Co LP | 0 | $0 | 0.00% | −25,930−100.0% | Sold out |
| SG3 Management, LLC | 0 | $0 | 0.00% | −25,000−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −20,231−100.0% | Sold out |
| DekaBank Deutsche Girozentrale | 0 | $0 | 0.00% | −19,800−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −18,014−100.0% | Sold out |
| Douglass Winthrop Advisors, LLC | 0 | $0 | 0.00% | −14,014−100.0% | Sold out |
| Concentric Capital Strategies, LP | 0 | $0 | 0.00% | −13,700−100.0% | Sold out |
| Cutler Group LP | 0 | $0 | 0.00% | −12,744−100.0% | Sold out |
| ProShare Advisors LLC | 0 | $0 | 0.00% | −12,296−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −10,275−100.0% | Sold out |
| Shay Capital LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Fox Run Management, L.L.C. | 0 | $0 | 0.00% | −8,926−100.0% | Sold out |
| Victory Capital Management Inc | 0 | $0 | 0.00% | −16,409−100.0% | Sold out |
| Group One Trading, L.P. | 0 | $0 | 0.00% | −4,500−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −3,834−100.0% | Sold out |
| BIT Capital GmbH | 0 | $0 | 0.00% | −3,800−100.0% | Sold out |
| Leonteq Securities AG | 0 | $0 | 0.00% | −480−100.0% | Sold out |
| US Bancorp | 0 | $0 | 0.00% | −118−100.0% | Sold out |
| Quadrant Capital Group LLC | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| Covestor Ltd | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| Parametric Portfolio Associates LLC | – | – | – | – | Not filed |
| Amalgamated Financial Corp. | – | – | – | – | Not filed |